Andrew Hopkins, Exscientia CEO

Ex­sci­en­tia tees up an IPO for its AI drug dis­cov­ery plat­form, like­ly not will­ing to set­tle for just $100M

The biotech IPO mar­ket awoke from its sum­mer hi­ber­na­tion on Fri­day morn­ing with a small AD­HD drug de­vel­op­er seek­ing a mod­est raise, but late Fri­day night saw an­oth­er com­pa­ny file its SEC pa­per­work, one that will like­ly shoot for the stars.

Ex­sci­en­tia, the UK-based AI out­fit with bold claims about its plat­form, sub­mit­ted its F-1 on Fri­day, pen­cil­ing in an ini­tial $100 mil­lion raise es­ti­mate. That fig­ure will al­most cer­tain­ly end up much high­er, as Ex­sci­en­tia has spent most of 2021 rack­ing up huge fundrais­ing sums thanks to a Se­ries C ex­ten­sion head­ed by Black­Rock, and an up to $525 mil­lion Se­ries D that in­clud­ed a $300 mil­lion eq­ui­ty in­vest­ment from Soft­Bank.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.